다중혈관 관상동맥 환자에서 y-문합을 이용하여 양쪽 내흉동맥만을 사용한 우회술의 조기 성적

ABCD
: Appropriate Blood pressure Control in Diabetes
ABI
: ankle–brachial index
ABPM
: ambulatory blood pressure monitoring
ACCESS
: Acute Candesartan Cilexetil Therapy in Stroke Survival
ACCOMPLISH
: Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension
ACCORD
: Action to Control Cardiovascular Risk in Diabetes
ACE
: angiotensin-converting enzyme
ACTIVE I
: Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
ADVANCE
: Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation
AHEAD
: Action for HEAlth in Diabetes
ALLHAT
: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack
ALTITUDE
: ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints
ANTIPAF
: ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation
APOLLO
: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
ARB
: angiotensin receptor blocker
ARIC
: Atherosclerosis Risk In Communities
ARR
: aldosterone renin ratio
ASCOT
: Anglo-Scandinavian Cardiac Outcomes Trial
ASCOT-LLA
: Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm
ASTRAL
: Angioplasty and STenting for Renal Artery Lesions
A-V
: atrioventricular
BB
: beta-blocker
BMI
: body mass index
BP
: blood pressure
BSA
: body surface area
CA
: calcium antagonist
CABG
: coronary artery bypass graft
CAPPP
: CAPtopril Prevention Project
CAPRAF
: CAndesartan in the Prevention of Relapsing Atrial Fibrillation
CHD
: coronary heart disease
CHHIPS
: Controlling Hypertension and Hypertension Immediately Post-Stroke
CKD
: chronic kidney disease
CKD-EPI
: Chronic Kidney Disease—EPIdemiology collaboration
CONVINCE
: Controlled ONset Verapamil INvestigation of CV Endpoints
CT
: computed tomography
CV
: cardiovascular
CVD
: cardiovascular disease
D
: diuretic
DASH
: Dietary Approaches to Stop Hypertension
DBP
: diastolic blood pressure
DCCT
: Diabetes Control and Complications Study
DIRECT
: DIabetic REtinopathy Candesartan Trials
DM
: diabetes mellitus
DPP-4
: dipeptidyl peptidase 4
EAS
: European Atherosclerosis Society
EASD
: European Association for the Study of Diabetes
ECG
: electrocardiogram
EF
: ejection fraction
eGFR
: estimated glomerular filtration rate
ELSA
: European Lacidipine Study on Atherosclerosis
ESC
: European Society of Cardiology
ESH
: European Society of Hypertension
ESRD
: end-stage renal disease
EXPLOR
: Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination
FDA
: U.S. Food and Drug Administration
FEVER
: Felodipine EVent Reduction study
GISSI-AF
: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation
HbA1c
: glycated haemoglobin
HBPM
: home blood pressure monitoring
HOPE
: Heart Outcomes Prevention Evaluation
HOT
: Hypertension Optimal Treatment
HRT
: hormone replacement therapy
HT
: hypertension
HYVET
: HYpertension in the Very Elderly Trial
IMT
: intima-media thickness
I-PRESERVE
: Irbesartan in Heart Failure with Preserved Systolic Function
INTERHEART
: Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries
INVEST
: INternational VErapamil SR/T Trandolapril
ISH
: Isolated systolic hypertension
JNC
: Joint National Committee
JUPITER
: Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin
LAVi
: left atrial volume index
LIFE
: Losartan Intervention For Endpoint Reduction in Hypertensives
LV
: left ventricle/left ventricular
LVH
: left ventricular hypertrophy
LVM
: left ventricular mass
MDRD
: Modification of Diet in Renal Disease
MRFIT
: Multiple Risk Factor Intervention Trial
MRI
: magnetic resonance imaging
NORDIL
: The Nordic Diltiazem Intervention study
OC
: oral contraceptive
OD
: organ damage
ONTARGET
: ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
PAD
: peripheral artery disease
PATHS
: Prevention And Treatment of Hypertension Study
PCI
: percutaneous coronary intervention
PPAR
: peroxisome proliferator-activated receptor
PREVEND
: Prevention of REnal and Vascular ENdstage Disease
PROFESS
: Prevention Regimen for Effectively Avoiding Secondary Strokes
PROGRESS
: Perindopril Protection Against Recurrent Stroke Study
PWV
: pulse wave velocity
QALY
: Quality adjusted life years
RAA
: renin-angiotensin-aldosterone
RAS
: renin-angiotensin system
RCT
: randomized controlled trials
RF
: risk factor
ROADMAP
: Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention
SBP
: systolic blood pressure
SCAST
: Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke
SCOPE
: Study on COgnition and Prognosis in the Elderly
SCORE
: Systematic COronary Risk Evaluation
SHEP
: Systolic Hypertension in the Elderly Program
STOP
: Swedish Trials in Old Patients with Hypertension
STOP-2
: The second Swedish Trial in Old Patients with Hypertension
SYSTCHINA
: SYSTolic Hypertension in the Elderly: Chinese trial
SYSTEUR
: SYSTolic Hypertension in Europe
TIA
: transient ischaemic attack
TOHP
: Trials Of Hypertension Prevention
TRANSCEND
: Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease
UKPDS
: United Kingdom Prospective Diabetes Study
VADT
: Veterans' Affairs Diabetes Trial
VALUE
: Valsartan Antihypertensive Long-term Use Evaluation
WHO
: World Health Organization

### 1.1 Principles

The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

/pdf/2013-esh-esc-guidelines-for-the-management-of-arterial-4ydvs5ifsx.pdf

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

The rapid technological developments of the past decade and the changes in echocardiographic practice brought about by these developments have resulted in the need for updated recommendations to the previously published guidelines for cardiac chamber quantification, which was the goal of the joint writing group assembled by the American Society of Echocardiography and the European Association of Cardiovascular Imaging. This document provides updated normal values for all four cardiac chambers, including three-dimensional echocardiography and myocardial deformation, when possible, on the basis of considerably larger numbers of normal subjects, compiled from multiple databases. In addition, this document attempts to eliminate several minor discrepancies that existed between previously published guidelines.

https://biblio.ugent.be/publication/5953422/file/5953443.pdf

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Probability Distributions.- Linear Models for Regression.- Linear Models for Classification.- Neural Networks.- Kernel Methods.- Sparse Kernel Machines.- Graphical Models.- Mixture Models and EM.- Approximate Inference.- Sampling Methods.- Continuous Latent Variables.- Sequential Data.- Combining Models.

Pattern Recognition and Machine Learning

We thank Tello et al.1 for their interest in our work in which we described a novel echocardiographic parameter (right ventricular free wall strain/pulmonary artery pressure ratio) to predict clinical outcome in pre-capillary pulmonary arterial hypertension patients. Right ventricular (RV) function is closely associated with mortality in all pulmonary hypertension groups. RV function has the ability to increase its contractility by adaptive mechanisms in response to increased afterload from the pulmonary vascular system during the disease process. However, at some point, the RV can no longer adapt to the increased afterload and RV failure occurs. The interrelation between the pulmonary vascular system and RV is described as RV-pulmonary artery (PA) coupling and has been presented as the ratio of RV function to pulmonary vascular afterload. The gold standard for measuring RV-PA coupling is obtaining the ratio of RV end-systolic elastance (Ees) to pulmonary arterial elastance (Ea) invasively, where Ees/Ea ratio represents coupling. To overcome the invasive nature and complexity of the measurement, several non-invasive methods have been proposed to estimate RV-PA coupling. The tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (sPAP) ratio was mostly investigated echocardiographic surrogate for RV-PA coupling.2,3 

Right ventriculo-arterial coupling assessed by right ventricular strain is a superior predictor of clinical outcome in patients with pulmonary arterial hypertension.

This editorial refers to ‘Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy’ D.-Y. Lu et al. pp. 487–95. Over two decades ago, strain and strain rate imaging was introduced to the world of clinical echocardiography.1 Post-processing of colour-tissue-Doppler was used to calculate myocardial deformation and deformation rate and allowed for the first time to quantify myocardial function on a regional (segmental) level. The method was immediately embraced by lovers of technological advances, but remained mainly a research tool. Focusing on regions of interest that had to be tracked manually throughout the cardiac cycle, the post-processing was time-consuming and not suited for a fast and comprehensive assessment of the entire left ventricle during a clinical routine examination. Nevertheless, strain and strain rate imaging has massively influence the way we look at myocardial function in echocardiography. We learned that regional dysfunction is more than hypo-,... 

Building up evidence.

Septal Scar Detection in Patients With Left Bundle Branch Block Using Echocardiographic Shear Wave Elastography.

Die Belastungsechokardiographie hat sich als Alternative zu nuklearmedizinischen Verfahren in der funktionellen Diagnostik bei koronarer Herzkrankheit bewahrt. Bei ihrer Evaluierung im Rahmen breiter klinischer Anwendung bleiben jedoch weiterhin drei methodenimmanente Probleme ungelost: 


Beurteilung der systolischen anstelle der diastolischen Myokardfunktion,


unzureichende Endokarderkennung zur Beurteilung der regionalen Wanddickenzunahme,


semiquantitatives Scoring anstelle von Quantifizierung.

Automatische Konturerkennung, Color Kinese und Myokard-Doppler


 
 
 Type of funding sources: None.
 Introduction - The high cost and important non-response rate are preventing optimal use of cardiac resynchronization therapy (CRT). Assessing mechanical dyssynchrony on echocardiography in candidates for CRT could remove these barriers by improving patient selection. In 2008 the PROSPECT study compared several old parameters of dyssynchrony in search of a reproducible parameter capable of better predicting response to CRT. Unfortunately, the results were disappointing and the assessment of dyssynchrony became discredited. Promising new parameters have been developed but a comparison with the old parameters is currently missing.
 Purpose - To compare the old and new parameters of mechanical dyssynchrony for (1) their effect on response to CRT as additional selection criteria, (2) predicting favourable long-term outcome after CRT and (3) their reproducibility.
 Methods - 146 CRT patients were analysed retrospectively in a multicentre setting. Mechanical dyssynchrony was assessed using three old parameters: septal-to-posterior wall motion delay (SPWMD), left ventricular filling time/cardiac cycle ratio (LVFT/RR), and intraventricular mechanical delay (IVMD); and three new parameters: systolic stretch index (SSI), myocardial work index (MWI), and visual presence of septal flash or apical rocking (SFoAR). Response to CRT was defined as a ≥15% decrease in LV end-systolic volume 1 year after CRT. For each parameter patients were categorized using previously published cut-offs as ‘eligible’ or ‘non-eligible’. The ‘non-eligible’ were considered untreated. Results were compared to the guidelines (Fig. 1). The hazard ratio (HR) for cardiac death within 5 years after implantation was computed for all patients (Fig. 2), and intra- and interrater agreement was determined.
 Results - 73% (n= 107) of patients showed response to CRT. The old parameters maintained less than 75% of the original responders. SFoAR preserved the highest proportion of responders (93%), while reducing the number of non-responders by 39% (Fig. 1). The prediction of cardiac death was significant for SFoAR (HR = 0.29; 95% CI: 0.12-0.74; P = 0.009) and IVMD (HR = 0.32; 95% CI: 0.13-0.79; P = 0.014) (Fig. 2). Intra- and interrater agreement was best for SFoAR (κ = 0.89; 95% CI: 0.67-1.0 and κ = 0.78; 95% CI: 0.50-1.0 respectively). Interrater agreement was poor for all old parameters (κ < 0.6).
 Conclusion - The new parameters for dyssynchrony are performing better. The visual presence of apical rocking or septal flash provided the most responders to CRT, predicted favourable long-term outcome and was highly reproducible. Our results show that future research should focus on the new parameters. Abstract Figure.  Abstract Figure.


Jens-Uwe Voigt

Papers

Right ventriculo-arterial coupling assessed by right ventricular strain is a superior predictor of clinical outcome in patients with pulmonary arterial hypertension.

Building up evidence.

Septal Scar Detection in Patients With Left Bundle Branch Block Using Echocardiographic Shear Wave Elastography.

Automatische Konturerkennung, Color Kinese und Myokard-Doppler

Echocardiographic assessment of mechanical dyssynchrony: are the new parameters better?